Perfluorocarbon oxygen carrier - Tenax Therapeutics

Drug Profile

Perfluorocarbon oxygen carrier - Tenax Therapeutics

Alternative Names: Oxycyte; Wundecyte

Latest Information Update: 20 Jan 2016

Price : $50

At a glance

  • Originator Synthetic Blood International
  • Developer Aurum Biosciences; Naval Medical Research Center; Oxygen Biotherapeutics
  • Class Cyclohexanes; Fluorocarbons; Small molecules
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Air embolism; Decompression sickness; Skin disorders; Stroke; Wounds
  • Discontinued Brain injuries; Hypoxia; Poisoning; Sickle cell anaemia; Spinal cord injuries

Most Recent Events

  • 19 Sep 2014 Oxygen Biotherapeutics is now called Tenax Therapeutics
  • 11 Sep 2014 No development reported - Preclinical for Wounds in USA (Topical)
  • 11 Sep 2014 No development reported - Preclinical for Stroke in Scotland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top